Evidence map›Paper›PMID 35455480›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

One-Year Outcome of Combination Therapy with Full or Reduced Photodynamic Therapy and One Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy.

Miki Sato-Akushichi, Shinji Ono, Tatsuro Taneda, Gerd Klose, Asuka Sasamori, Youngseok Song

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Six-month outcomes of half-fluence photodynamic therapy combined with intravitreal Aflibercept injection for pachychoroid neovasculopathy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025
    Article
  3. Article
  4. Review
  5. Intravitreal anti-vascular endothelial growth factor and combined photodynamic therapy for pachychoroid neovasculopathy: long-term treatment outcomes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2024
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Miki Sato-AkushichiDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa 078-8510, Japan.ORCID 0000-0002-5150-1468
Shinji OnoDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa 078-8510, Japan.
Tatsuro TanedaDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa 078-8510, Japan.
Gerd KloseCarl Zeiss Meditec, Inc., Dublin, CA 94568, USA.
Asuka SasamoriNayoro City General Hospital, Nayoro 096-0017, Japan.
Youngseok SongDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa 078-8510, Japan.ORCID 0000-0003-3294-3671
Asahikawa Medical University · JPCarl Zeiss (United States) · USNayoro City General Hospital · JP

Funding

Ministry of Education, Culture, Sports, Science and Technology 20K18333
6 · The paper itself

Abstract

This paper evaluates a one-year treatment outcome after full or reduced photodynamic therapy (PDT) and anti-vascular endothelial growth factor (VEGF) combination therapy for pachychoroid neovasculopathy (PNV). After the initial combination therapy, a total of 29 eyes from 29 patients (16 for full treatment and 13 for reduced treatment), exhibited reduced, central retinal thickness and central choroidal thickness, and the improvements were maintained for 1 year after the initial combination therapy. Twenty-two eyes (75.9%) required no additional treatments for 1 year. The recurrence rate was 31.3% in the full treatment and 15.4% in the reduced treatment, with no significant differences between them. One shot of anti-VEGF and full or reduced PDT combination therapy had similar efficacy in treating PNV. Further prospective, large-scale, and long-term studies are required to determine a better treatment for PNV.

Indexed as

anti-vascular endothelial growth factorcombination therapypachychoroid neovasculopathyphotodynamic therapy

Identifiers

PMID35455480
PMCPMC9027184
OpenAlexW4224243688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.